Revefenacin Production Cost Reports

The report provides a detailed analysis essential for establishing a Revefenacin production plant. It encompasses all critical aspects necessary for Revefenacin production, including the cost of Revefenacin production, Revefenacin plant cost, Revefenacin production costs, and the overall Revefenacin production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Revefenacin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Revefenacin is a long acting muscarinic antagonist (LAMA) bronchodilator. It is used by inhalation for maintenance treatment of chronic obstructive pulmonary disease (COPD), like chronic bronchitis and emphysema, but not for sudden breathing attacks.

It is used as a nebulised solution that selectively blocks M3 muscarinic receptors in airway smooth muscle, causing sustained bronchodilation over 24 hours. It helps reduce bronchospasm, improve lung function, and lessen symptoms like breathlessness, chronic cough, and exercise limitation. Its nebuliser version is mainly useful for older or more severe COPD patients who struggle with handheld inhalers, and it is often used alone or in combination with other maintenance therapies.

The market for Revefenacin is driven by the rising global burden of COPD. The growth in elderly populations, higher air pollution, and smoking exposure contribute to its demand. Also, a rise in the need for once daily nebulised bronchodilators for patients who struggle with handheld inhalers fuels the market.

The industrial Revefenacin procurement is influenced by a concentrated API and finished dose supplier base, along with strict respiratory and GMP regulatory requirements. Its price dynamics are affected by negotiated rebates, hospital tenders, and country specific reimbursement. Other factors like long lead times for inhalation products, sensitivity to forecasting errors for chronic therapies, and dependence on a few sites for API and FDF impact its sourcing.

Raw Material for Revefenacin Production

According to the Revefenacin production plant project report, the key raw materials used in the production of Revefenacin include Isonipecotamide, Acetic Acid, Sodium Sulfate, Isopropanol, and Sodium Triacetoxyborohydride.

Production Process of Revefenacin

The extensive Revefenacin production cost report consists of the following major industrial production process:

1. From Isonipecotamide: The production process of Revefenacin involves several steps. First, Isonipecotamide, acetic acid, sodium sulfate, and isopropanol are mixed and cooled to 0-10 degree Celsius with an ice bath. To this mixture, a solution of isopropanol containing the product compound is added. The reaction is stirred, followed by the addition of sodium triacetoxyborohydride. The mixture is concentrated under reduced pressure and acidified to pH 3, stirred at room temperature, and extracted with DCM. The aqueous phase is cooled and extracted with isopropyl acetate, washed with water and brine, dried over anhydrous sodium sulfate, to get Revefenacin as the final product.

Revefenacin is a long-acting muscarinic antagonist used in nebulised form for COPD. It exists as a solid with the molecular formula C35H43N5O4 and a molecular weight of 597.76 g/mol. It has a predicted boiling point of 777.5 degree Celsius and a density of around 1.26 g/cm³. It has a high solubility in DMSO but low water solubility. It has a logP value of 3.22, making it moderately lipophilic. It has a biphenyl carbamate tertiary amine structure with five rings, a polar surface area of 108.21 Ų. It has two hydrogen bond donors, six acceptors and a pKa value of 8.65 (basic). It shows extensive tissue distribution, with 71% plasma protein binding.